Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Arcus Biosciences, Inc.
Poseida Therapeutics, Inc.
Seagen Inc.
Novartis
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
EMD Serono
University Health Network, Toronto
National Cancer Institute (NCI)
University Health Network, Toronto
NeoTX Therapeutics Ltd.
TScan Therapeutics, Inc.
National Cancer Institute (NCI)
SystImmune Inc.
Oncoinvent Solutions AS
Exelixis
Nuvectis Pharma, Inc.
Toray Industries, Inc
Arsenal Biosciences, Inc.
Daiichi Sankyo
Dana-Farber Cancer Institute
Compugen Ltd
National Cancer Institute (NCI)
St Vincent's Hospital, Sydney
Virginia Commonwealth University
Roswell Park Cancer Institute
Agenus Inc.
Carisma Therapeutics Inc
Sunnybrook Health Sciences Centre
Precigen, Inc
Revolution Medicines, Inc.
Shanghai PerHum Therapeutics Co., Ltd.
NGM Biopharmaceuticals, Inc
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
University Medical Center Groningen
NGM Biopharmaceuticals, Inc
Adaptimmune